Antimetabolite Treatment for Pancreatic Cancer.

about

Reconstruction of Tissue-Specific Metabolic Networks Using CORDA Cell death in response to antimetabolites directed at ribonucleotide reductase and thymidylate synthase DNMT1 Inhibition Reprograms Pancreatic Cancer Stem Cells via Upregulation of the miR-17-92 Cluster.

P2860

Q28388815-0789A01B-38D9-4958-A8C9-9B6033353C2A Q35161704-B34FECAA-9FC5-41A2-9E36-589AEA9DA3DB Q37629380-4E908F1A-21CE-443B-83F1-DE83C8B26324

P2860

Antimetabolite Treatment for Pancreatic Cancer.

Item

http://www.wikidata.org/entity/Q35826334

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Antimetabolite Treatment for Pancreatic Cancer.

@ast

Antimetabolite Treatment for Pancreatic Cancer.

@en

type

Item

label

Antimetabolite Treatment for Pancreatic Cancer.

@ast

Antimetabolite Treatment for Pancreatic Cancer.

@en

prefLabel

Antimetabolite Treatment for Pancreatic Cancer.

@ast

Antimetabolite Treatment for Pancreatic Cancer.

@en

P1476

Antimetabolite Treatment for Pancreatic Cancer.

@en

P2093

Jonathan W Neidigh

http://www.w3.org/2001/XMLSchema#string

Malyn May Asuncion Valenzuela

http://www.w3.org/2001/XMLSchema#string

Nathan R Wall

http://www.w3.org/2001/XMLSchema#string

P2860

Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.

5-fluorouracil: mechanisms of action and clinical strategies

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds

Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Cisplatin: mode of cytotoxic action and molecular basis of resistance

Pancreatic cancer

A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin.

Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study.

A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer.

P31

scholarly article

P356

10.4172/2167-7700.1000137

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277351458

http://www.w3.org/2001/XMLSchema#string

P698

26161298

http://www.w3.org/2001/XMLSchema#string

P932

4494102

http://www.w3.org/2001/XMLSchema#string

Antimetabolite Treatment for Pancreatic Cancer.

about

P2860

P2860

Antimetabolite Treatment for Pancreatic Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P577

P5875

P698

P932